Azafaros has raised €132 million in an oversubscribed Series B financing round. The funding will support the advancement of its lead clinical-stage asset, AZ-3102, into two Phase 3 trials for the treatment of rare lysosomal storage disorders: GM1 and GM2 gangliosidosis.
This significant milestone marks one of the largest private biotech financings in Europe so far in 2025. The round was led by Forbion Growth and included new investors such as Sofinnova Partners, as well as strategic investor Sarepta Therapeutics, alongside existing investors.
With this financing, Azafaros is poised to accelerate late-stage development of innovative therapies that target multiple neurological symptoms of rare genetic diseases, bringing new hope to patients and families affected by these devastating conditions.
Read more here
Dura Vermeer Commercieel Vastgoed and Cellares has signed a long-term lease for a new IDMO Smart Factory in building Nexus (9,741 sqm LFA) at Leiden Bio Science Park. The...
The successful program for stimulating digitization in small and medium-sized businesses in the Leiden and Katwijk region is getting a sequel. Key Region Leiden, in cooperation...
Leiden, 8 January 2026 – Two scientific projects from Leiden University and LUMC have received funding from Open Science NL. The aim is to make science more accessible to...